{"id":"gsk1349572-dolutegravir","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dolutegravir is an integrase strand transfer inhibitor (INSTI) that binds to the active site of HIV integrase and blocks the enzyme's ability to catalyze the integration of viral DNA into the host cell genome. By preventing this critical step in the HIV replication cycle, the drug stops viral propagation and reduces viral load in infected individuals.","oneSentence":"Dolutegravir inhibits HIV integrase, preventing the virus from inserting its genetic material into human DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:42.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve adults"},{"name":"HIV-1 infection in treatment-experienced adults"}]},"trialDetails":[{"nctId":"NCT05652478","phase":"PHASE2","title":"Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Healthy Volunteer, Weight Gain, Metabolic Effects","enrollment":120},{"nctId":"NCT06253715","phase":"PHASE3","title":"Shortened Regimen for Drug-susceptible TB in Children","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-01-15","conditions":"Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node","enrollment":860},{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT05373758","phase":"NA","title":"A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-02-07","conditions":"HIV Infections, AIDS, Virologic Failure","enrollment":648},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT07202546","phase":"PHASE2","title":"A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)","status":"RECRUITING","sponsor":"ViiV Healthcare","startDate":"2026-02-11","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT07001319","phase":"PHASE1","title":"Study of GS-3242 in Participants With HIV-1; Substudy-05","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-05-29","conditions":"HIV-1-infection","enrollment":30},{"nctId":"NCT05993767","phase":"PHASE2","title":"UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2024-12-11","conditions":"HIV Infection","enrollment":53},{"nctId":"NCT04337450","phase":"PHASE2, PHASE3","title":"DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"PENTA Foundation","startDate":"2022-04-22","conditions":"HIV Infections","enrollment":386},{"nctId":"NCT05393193","phase":"PHASE4","title":"POC HIV Testing and Early DTG Use for Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2022-07-04","conditions":"HIV","enrollment":900},{"nctId":"NCT05630638","phase":"PHASE4","title":"Doravirine Dose Optimisation in Pregnancy","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2023-10-10","conditions":"HIV","enrollment":76},{"nctId":"NCT04991402","phase":"","title":"Obesogenic Origins of Maternal and Child Metabolic Health Involving Dolutegravir","status":"COMPLETED","sponsor":"Columbia University","startDate":"2021-09-21","conditions":"HIV, Obesity, Obesity, Infant","enrollment":1920},{"nctId":"NCT07393659","phase":"PHASE3","title":"A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment","status":"NOT_YET_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2026-05-08","conditions":"HIV Infections","enrollment":183},{"nctId":"NCT03016533","phase":"PHASE3","title":"Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-06-06","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT07124559","phase":"PHASE1, PHASE2","title":"A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-05-15","conditions":"Tuberculosis","enrollment":144},{"nctId":"NCT07336797","phase":"PHASE2","title":"Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy","status":"RECRUITING","sponsor":"Abdelrahman Mahmoud","startDate":"2025-09-01","conditions":"Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)","enrollment":66},{"nctId":"NCT06203132","phase":"PHASE3","title":"DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-01-27","conditions":"HIV-1-infection","enrollment":610},{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT05122767","phase":"PHASE1, PHASE2","title":"Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2023-05-24","conditions":"Tuberculosis, HIV","enrollment":92},{"nctId":"NCT05122026","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Aurum Institute NPC","startDate":"2024-01-17","conditions":"HIV Seropositivity, Pregnancy, Tuberculosis Infection","enrollment":252},{"nctId":"NCT05642481","phase":"","title":"Therapeutic Drug Monitoring to oPtimize ANtiretroviral regimeNs in HIV-infected Women Who wAnt to Breastfeed","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2023-03-01","conditions":"HIV-1-infection","enrollment":16},{"nctId":"NCT03682848","phase":"PHASE3","title":"Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-05-06","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT05630872","phase":"PHASE2","title":"Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-02-13","conditions":"HIV-associated Tuberculosis","enrollment":30},{"nctId":"NCT05979311","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2024-02-09","conditions":"HIV, HIV Infections","enrollment":473},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT04771754","phase":"PHASE1","title":"The Effect of Dolutegravir on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers","status":"COMPLETED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2022-03-20","conditions":"HIV-1-infection on Healthy Volunteers","enrollment":16},{"nctId":"NCT05069688","phase":"PHASE1","title":"Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-07-07","conditions":"Pediatric HIV Infection, Tuberculosis Infection","enrollment":20},{"nctId":"NCT05911360","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-01-31","conditions":"HIV, HIV Infections","enrollment":205},{"nctId":"NCT06285110","phase":"","title":"HIV-1 Subtype-specific Drug Resistance in Patients Failing Dolutegravir (DTG) Based Regimen","status":"COMPLETED","sponsor":"University of Bern","startDate":"2022-06-13","conditions":"Hiv","enrollment":1103},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT07115368","phase":"PHASE1","title":"Study of GS-1219 in Participants With HIV-1","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2025-08-11","conditions":"HIV-1-infection","enrollment":4},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT04734652","phase":"PHASE2","title":"INSTI's For The Management of HIV-associated TB","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-02-18","conditions":"HIV/AIDS, Tuberculosis, Pulmonary","enrollment":122},{"nctId":"NCT03360682","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients","status":"COMPLETED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2018-04-13","conditions":"HIV-1-infection, Solid Organ Transplant","enrollment":19},{"nctId":"NCT06497465","phase":"PHASE3","title":"Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-09-18","conditions":"Tuberculosis, HIV","enrollment":150},{"nctId":"NCT03194165","phase":"","title":"Population Pharmacokinetics of Antiretroviral in Children","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-16","conditions":"Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed","enrollment":65},{"nctId":"NCT06967753","phase":"PHASE4","title":"Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH)","status":"RECRUITING","sponsor":"UBATEC","startDate":"2025-07-31","conditions":"HIV, HIV-1","enrollment":50},{"nctId":"NCT06005610","phase":"PHASE2","title":"Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-01-04","conditions":"HIV I Infection","enrollment":93},{"nctId":"NCT06747507","phase":"PHASE3","title":"Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance","status":"RECRUITING","sponsor":"University of Nairobi","startDate":"2025-09-01","conditions":"HIV-1-infection","enrollment":392},{"nctId":"NCT06762054","phase":"","title":"Investigating the Optimal Management of Dolutegravir Resistance","status":"RECRUITING","sponsor":"University of Nairobi","startDate":"2025-03-03","conditions":"HIV-1-infection","enrollment":6600},{"nctId":"NCT06444620","phase":"PHASE3","title":"B/F/TAF to DTG/3TC Switch Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Nairobi","startDate":"2024-07-22","conditions":"HIV-1-infection","enrollment":240},{"nctId":"NCT02245022","phase":"PHASE2, PHASE3","title":"Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2017-03-14","conditions":"HIV, Pregnancy","enrollment":60},{"nctId":"NCT05406583","phase":"PHASE1","title":"A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-10-05","conditions":"HIV","enrollment":48},{"nctId":"NCT07138144","phase":"PHASE4","title":"Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up","status":"RECRUITING","sponsor":"José Antonio Mata Marín","startDate":"2025-07-12","conditions":"HIV Infections","enrollment":156},{"nctId":"NCT03754803","phase":"","title":"Description of Real World Antiviral Effectiveness and Sustainability of the 2-Drug Regimen Dolutegravir + Lamivudine in Untreated and Pre-treated Patients in Routine Clinical Care in Germany","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-11-08","conditions":"HIV Infections","enrollment":376},{"nctId":"NCT06805656","phase":"PHASE2","title":"Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals","status":"NOT_YET_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2025-09-01","conditions":"Hiv, HIV I Infection","enrollment":70},{"nctId":"NCT07110831","phase":"PHASE4","title":"Disposition Kinetics of Dolutegravir Among People Living With HIV With Major Depression in Nigeria","status":"NOT_YET_RECRUITING","sponsor":"University of Ibadan","startDate":"2025-08-14","conditions":"Depression, HIV","enrollment":168},{"nctId":"NCT04453436","phase":"","title":"HIV Drug Resistance Among Individuals Failing Tenofovir/Lamivudine and Dolutegravir First Line Regimen in Brazil","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2023-09-01","conditions":"HIV, Drug, Resistance","enrollment":2500},{"nctId":"NCT04880395","phase":"PHASE4","title":"Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3","status":"COMPLETED","sponsor":"Fundación Huésped","startDate":"2021-05-17","conditions":"HIV-1-infection","enrollment":265},{"nctId":"NCT02259127","phase":"PHASE2, PHASE3","title":"ODYSSEY (PENTA 20)","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2016-09-20","conditions":"HIV Infection","enrollment":792},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT05898841","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2023-05-26","conditions":"HIV Infections, Fatty Liver Disease","enrollment":63},{"nctId":"NCT04884139","phase":"PHASE4","title":"DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV:","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2021-07-14","conditions":"HIV-1-infection","enrollment":554},{"nctId":"NCT05729568","phase":"PHASE2","title":"A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2023-05-15","conditions":"HIV Infection","enrollment":83},{"nctId":"NCT05193994","phase":"PHASE3","title":"Triumeq in Amyotrophic Lateral Sclerosis","status":"TERMINATED","sponsor":"Macquarie University, Australia","startDate":"2022-02-24","conditions":"Amyotrophic Lateral Sclerosis","enrollment":419},{"nctId":"NCT02285114","phase":"PHASE2, PHASE3","title":"Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-20","conditions":"HIV-1","enrollment":41},{"nctId":"NCT06787976","phase":"PHASE4","title":"Effect of Dolutegravir Compared With Darunavir/Cobicistat on the Severity of Neuropsychiatric Effects al 12 Weeks in Antirretroviral Treatment-Naive Adults.","status":"NOT_YET_RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-06-19","conditions":"HIV, Insomnia, Anxiety","enrollment":140},{"nctId":"NCT07031063","phase":"PHASE4","title":"Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-04-01","conditions":"HIV Infection, Metabolic Syndrome, Antiretroviral Treatment","enrollment":124},{"nctId":"NCT06640192","phase":"PHASE2","title":"Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir","status":"RECRUITING","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2025-05-30","conditions":"HIV-1-infection","enrollment":24},{"nctId":"NCT02656511","phase":"PHASE4","title":"Immediate Initiation of Antiretroviral Therapy During \"Hyperacute\" HIV Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2015-12","conditions":"HIV","enrollment":74},{"nctId":"NCT06774872","phase":"PHASE2","title":"Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully","status":"RECRUITING","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2025-04-30","conditions":"HIV-1-infection","enrollment":408},{"nctId":"NCT06658977","phase":"PHASE3","title":"RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial","status":"TERMINATED","sponsor":"Macquarie University, Australia","startDate":"2024-11-15","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":12},{"nctId":"NCT00796263","phase":"PHASE3","title":"Antiretroviral Therapy for Acute and Chronic HIV Infection","status":"RECRUITING","sponsor":"SEARCH Research Foundation","startDate":"2009-05-13","conditions":"Acute HIV Infection, Chronic HIV Infection","enrollment":900},{"nctId":"NCT07002229","phase":"PHASE1","title":"A Clinical Study of the Interactions Between Azvudine Tablets (FNC) and Dolutegravir Sodium Tablets (DTG)","status":"COMPLETED","sponsor":"Henan Genuine Biotech Co., Ltd.","startDate":"2021-12-09","conditions":"Healthy","enrollment":15},{"nctId":"NCT06607588","phase":"","title":"Selection of Resistant Mutations to Dolutegravir in PLWH Treated in Mozambique","status":"RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2024-10-25","conditions":"HIV, HIV Antiretroviral Therapy (ART) Adherence","enrollment":200},{"nctId":"NCT05585307","phase":"PHASE1","title":"Study of Novel Antiretrovirals in Participants With HIV-1","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2022-10-26","conditions":"HIV-1-infection","enrollment":49},{"nctId":"NCT06928090","phase":"","title":"Efficacy and Safety of DTG/3TC in Treatment-naïve HIV-1 Infected Patients","status":"ENROLLING_BY_INVITATION","sponsor":"Chungnam National University Hospital","startDate":"2025-01-24","conditions":"HIV","enrollment":200},{"nctId":"NCT05044962","phase":"NA","title":"Kuwa Free! - Live Free!","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-26","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":700},{"nctId":"NCT05924438","phase":"PHASE3","title":"A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Professor Francois Venter","startDate":"2023-11-08","conditions":"HIV-1-infection","enrollment":600},{"nctId":"NCT04442737","phase":"PHASE4","title":"A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2020-07-01","conditions":"HIV-1","enrollment":103},{"nctId":"NCT03547908","phase":"PHASE3","title":"Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-05-30","conditions":"HIV-1/HBV Co-Infection","enrollment":244},{"nctId":"NCT04034862","phase":"PHASE3","title":"Impact of DOlutegravir+Lamivudine Simplification on HIV-1 Reservoirs","status":"COMPLETED","sponsor":"University of Liege","startDate":"2019-10-01","conditions":"HIV Infections","enrollment":36},{"nctId":"NCT04487145","phase":"PHASE4","title":"Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2020-11-23","conditions":"Drug-Drug Interaction, HIV Infection","enrollment":194},{"nctId":"NCT04880785","phase":"PHASE2","title":"Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2021-07-28","conditions":"HIV Infections","enrollment":121},{"nctId":"NCT03249181","phase":"PHASE3","title":"Dolutegravir in Pregnant HIV Mothers and Their Neonates","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2018-01-22","conditions":"HIV-1-infection, Pregnancy Related","enrollment":268},{"nctId":"NCT04862975","phase":"","title":"Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-01-09","conditions":"Lactating Women on Select DOI, Breastmilk Fed Infants of Mothers on Select DOI, HIV Infections","enrollment":164},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT04012931","phase":"PHASE2","title":"A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-07-18","conditions":"HIV","enrollment":26},{"nctId":"NCT04019873","phase":"","title":"'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-11-18","conditions":"HIV Infections","enrollment":774},{"nctId":"NCT05426421","phase":"","title":"Tolerability of Lopinavir Versus Dolutegravir for Children and Adolescents Living With HIV","status":"COMPLETED","sponsor":"Swiss Tropical & Public Health Institute","startDate":"2022-07-11","conditions":"HIV","enrollment":258},{"nctId":"NCT03675815","phase":"PHASE4","title":"Body Composition Sub-study of the D2EFT Trial","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2019-12-05","conditions":"HIV Infections","enrollment":155},{"nctId":"NCT02987530","phase":"PHASE3","title":"National Multicenter Trial Evaluating Two Treatments in Patients with Primary Human Immunodeficiency Virus (HIV-1) Infection","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2017-04-11","conditions":"HIV-1 Infection","enrollment":101},{"nctId":"NCT05349838","phase":"PHASE3","title":"Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N","status":"COMPLETED","sponsor":"NEAT ID Foundation","startDate":"2018-11-05","conditions":"HIV-1-infection","enrollment":140},{"nctId":"NCT06281834","phase":"PHASE1","title":"Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-11-15","conditions":"Pediatric HIV Infection, Latent Tuberculosis","enrollment":25},{"nctId":"NCT04707326","phase":"","title":"Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2019-11-01","conditions":"Hiv","enrollment":2040},{"nctId":"NCT01302847","phase":"PHASE1, PHASE2","title":"Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-04-20","conditions":"HIV Infections","enrollment":181},{"nctId":"NCT05289986","phase":"PHASE4","title":"The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients","status":"TERMINATED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2023-11-21","conditions":"Hiv","enrollment":18},{"nctId":"NCT05584397","phase":"","title":"Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART","status":"ENROLLING_BY_INVITATION","sponsor":"University of Washington","startDate":"2022-09-01","conditions":"HIV-1-infection, HIV Disease Progression, Inflammation","enrollment":40},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT04585737","phase":"PHASE4","title":"Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF","status":"COMPLETED","sponsor":"Charlotte-Paige Rolle, MD","startDate":"2020-10-05","conditions":"HIV I Infection","enrollment":222},{"nctId":"NCT03518060","phase":"","title":"Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-06-25","conditions":"HIV Infections","enrollment":209},{"nctId":"NCT06637813","phase":"","title":"Establishment of a Database of HIV Subjects Initiating or Simplifying Dual Therapy With Dolutegravir/Lamivudine","status":"NOT_YET_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-10-30","conditions":"HIV -1 Infection","enrollment":1220},{"nctId":"NCT04871113","phase":"PHASE2","title":"A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2021-06-22","conditions":"HIV Infections","enrollment":62},{"nctId":"NCT06629480","phase":"NA","title":"Incidence of Metabolic Syndrome in People Living With HIV Without ExperienCe to ART Who Start DoLutegravir Based-Regimen Compared With BictegrAvir Based-RegimeN","status":"COMPLETED","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2021-06-25","conditions":"Antiretroviral Treatment, HIV Infection, Metabolic Cardiovascular Syndrome","enrollment":378},{"nctId":"NCT03731559","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetics of DTG with RIF","status":"RECRUITING","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2019-06-25","conditions":"HIV/TB Coinfection","enrollment":200},{"nctId":"NCT03991013","phase":"PHASE2","title":"Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2019-08-08","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT06619288","phase":"","title":"Good-first: B/F/TAF As First-line ART","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2024-07-01","conditions":"HIV Infection","enrollment":630}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CONFUSIONAL STATE"},{"count":1,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"HALLUCINATION, VISUAL"}],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSK1349572 (dolutegravir)","genericName":"GSK1349572 (dolutegravir)","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dolutegravir inhibits HIV integrase, preventing the virus from inserting its genetic material into human DNA. Used for HIV-1 infection in treatment-naïve adults, HIV-1 infection in treatment-experienced adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}